Skip to main content

Table 1 Results of univariate analysis

From: Long-term use of selective digestive decontamination in an ICU highly endemic for bacterial resistance

Variables Non-SDD cohort (n = 110) SDD cohort (n = 258) P value
Male sex 74 (67.3) 166 (64.3) 0.589
Age, years, mean ± SD 59.5 ± 15.8 60.7 ± 16.4 0.539
APACHE II score on admission, mean ± SD 21.2 ± 7.7 22.0 ± 7.7 0.345
Glasgow Coma Scale score, median (IQR) 15 (8–15) 14.5 (8–15) 0.098
Diagnosis on ICU admission    0.289
 Medical 79 (71.8) 190 (73.6)  
 Scheduled surgery 10 (9.1) 33 (12.8)  
 Emergency surgery 21 (19.1) 35 (13.6)  
Septic response    0.399
 Sepsis 57 (52.8) 110 (45.45)  
 Septic shock 51 (47.2) 132 (54.55)  
Prior surgery 18 (16.4) 37 (14.3) 0.618
Urgent surgery 34 (30.9) 70 (27.1) 0.461
Trauma patients 17 (15.5) 31 (12.0) 0.370
Current smokers 21 (19.1) 31 (27.4) 0.141
Underlying illness
 Diabetes mellitus 34 (30.9) 86 (33.3) 0.650
 Coronary artery disease 19 (17.3) 45 (17.4) 0.969
 Chronic liver disease 6 (5.5) 18 (7.0) 0.588
 Chronic obstructive lung disease 9 (8.2) 43 (16.7) 0.032
 Solid neoplasm 10 (9.1) 26 (10.1) 0.771
 Chronic renal failure 40 (36.4) 56 (21.7) 0.003
 Renal replacement therapy 34 (30.9) 91 (35.3) 0.419
 Parenteral nutrition 26 (23.6) 50 (19.4) 0.356
 Immunosuppression 8 (7.3) 22 (8.5) 0.687
 Malnutrition 12 (10.9) 24 (9.3) 0.635
ICU-acquired infection
 VAP 59 (53.6) 102 (39.5) 0.013
 CLABSI 26 (23.6) 106 (41.1) 0.001
 Secondary BSI 31 (28.2) 47 (18.2) 0.023
 Urinary tract infection 29 (26.4) 73 (28.3) 0.705
Infections caused by MDRB
 Gram-negative bacilli 12 (10.9) 8 (3.1) 0.002
Acinetobacter spp. 13 (11.8) 3 (1.2) <  0.001
 ESBL-producing MDRB 38 (34.5) 62 (24.0) 0.038
Pseudomonas aeruginosa 10 (9.1) 23 (8.9) 0.957
 Methicillin-resistant Staphylococcus aureus 4 (3.6) 5 (1.9) 0.460
ICU stay, days, median (IQR) 28 (16–45) 33 (17–50) 0.192
ICU mortality 36 (32.7) 85 (33.2) 0.929
  1. Abbreviations: SDD Selective digestive tract decontamination, ICU Intensive care unit, APACHE Acute Physiology and Chronic Health Evaluation, VAP Ventilator-associated pneumonia, CLABSI Central line-associated bloodstream infection, BSI Bloodstream infection, MDRB Multidrug-resistant bacteria, ESBL Extended-spectrum β-lactamase
  2. Data are expressed as frequency and percent unless otherwise stated
\